SCHEMBL26627413

SCHEMBL26627413

Cc1cccnc1-c1nc(C(N)=O)cs1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 1/20 0.51
▸ ACHE P22303 1/20 0.50
▸ PIM1 P11309 3/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ TGFBR1 P36897 1/20 0.43
▸ TLR7 Q9NYK1 5/20 0.42
▸ IRAK4 Q9NWZ3 1/20 0.42
▸ HTR2C P28335 1/20 0.40
▸ PTGER1 P34995 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28216860 0.79 HTR2B (0.69) HTR2BACHECYP2C19IRAK4HTR2C
Ammonia Solution, Strong SCHEMBL27976670 0.78 HTR2B (0.68) HTR2BACHECYP2C19IRAK4HTR2C
SCHEMBL31351218 0.75 HTR2B (0.60) HTR2BACHECYP2C19TLR7
SCHEMBL17515109 0.75 CYP2A6 (0.46) TGFBR1
SCHEMBL2100275 0.75 HTR2B (0.59) HTR2BACHECYP2C19TLR7ALDH1A1
SCHEMBL22583027 0.74 CYP2A6 (0.41) PIM1TGFBR1
SCHEMBL29435604 0.74 CYP2A6 (0.41) PIM1TGFBR1
SCHEMBL21553220 0.74 PIM1 (0.51) PIM1TLR7IRAK4
SCHEMBL13726372 0.74 ADORA3 (0.41) TGFBR1
SCHEMBL28309488 0.74 TGFBR1 (0.48) TGFBR1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024082724-A1 PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2024-04-25 — — WO disclosed
WO-2023202563-A1 AKT INHIBITOR IN COMBINATION WITH PIM KINASE INHIBITOR NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-10-26 — — WO disclosed
Send feedback